CGCP yields 5.16% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 10
Combined, CGCP + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CGCP + JNJ for your $10,000?
The fund's investment objective is to provide current income and seek maximum total return, consistent with preservation of capital.Distinguishing Characteristics Government debt and agency bonds, corporate bonds, mortgage- and asset-backed securities, emerging markets debt, non-U.S., municipals and high-yield.The bond maturities that the fund targets will vary depending on the current strategy being implemented.The fund may invest no more than 35% of its assets in securities rated below investment grade (BB+/Ba1 and below, or unrated, but determined by the fund's investment adviser to be of equivalent quality) at the time of purchase, including high-yield corporate bonds or those issued by developing country governments and companies. The fund may invest up to 10% of its assets in equity securities and certain securities with a combination of debt and equity characteristics. The fund may invest up to 35% of its assets in securities denominated in currencies other than the U.S. dollar. The fund may invest up to 35% of its assets in securities of emerging market issuers.
Full CGCP Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.